Drug intelligence / Profile preview

HEC93077

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

HEC93077 is an orally administered small molecule drug candidate developed by Sunshine Lake Pharma. It is being investigated primarily for the treatment of hyperuricemia (high uric acid levels), which is often associated with gout and other metabolic disorders. The drug has completed Phase 1 clinical trials in China, where its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and food effect were evaluated in both healthy volunteers and patients with hyperuricemia. The precise mechanism of action for HEC93077 remains undisclosed or unknown at this time[1][2][3].

Beyond the preview

Go deeper on HEC93077.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC93077.

Explore the full profile